Rigel Pharmaceuticals, Inc. (RIGL) vs SpyGlass Pharma, Inc. Common Stock (SGP)

A side-by-side comparison of Rigel Pharmaceuticals, Inc. and SpyGlass Pharma, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — RIGL vs SGP

growth of $100 · dividends reinvested · last 1y
RIGL +37.1% (+37.1%/yr)SGP -3.1% (-3.1%/yr)RIGL compounded faster over this window
80100120140Start $100$137$97
RIGL SGP

RIGL vs SGP: by the numbers

  • •RIGL is the larger company ($859M vs $840M market cap).
  • •RIGL is profitable (116.30% net margin) while SGP runs a net loss (0.00%).

Metrics side by side

Valuation

MetricRIGLSGP
P/E ratio2.84N/A
Forward P/E13.54N/A
P/S ratio3.10N/A
P/B ratio2.023.62
EV / EBITDA9.34N/A
FCF yield9.24%N/A

Profitability

MetricRIGLSGP
Gross margin91.39%0.00%
Operating margin42.63%0.00%
Net margin116.30%0.00%
ROE75.67%-24.12%
ROIC18.72%-26.54%

Growth (annualized)

MetricRIGLSGP
Revenue CAGR (5Y)13.94%N/A
Total return CAGR (5Y)6.25%N/A

Frequently asked

Is RIGL or SGP more profitable?
RIGL runs the higher net margin — RIGL at 116.30% versus SGP at 0.00%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.